CD163 and neoplasm: Nonetheless we performed, an immunoscore assessment of the immune system-based biomarkers including CD3, CD20, CD14 and CD163 which showed that, with the exception of focal immunoreactivity for CD3 in one case (see below), the samples were negative for the first two markers, and revealed scattered clusters of CD14 and CD163 restricted to the tumor stroma in three cases (DSRCT2, DSRCT4, DSRCT6 cases, Supplementary Table 2).